Status:
UNKNOWN
Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis
Lead Sponsor:
University of Pavia
Conditions:
Hypertension
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
Angiotensin II has been proposed as a lipid metabolism regulator. It is known that adipocytes secrete a variety of protein, such as TNFα, plasminogen activator inhibitor (PAI)-1, leptin, resistin and ...
Eligibility Criteria
Inclusion
- Gender: 50% Male and 50% female
- Age: 40-80 years
- Race: Caucasian
- Overweight or obese: respectively BMI25-30 kg/m2 or BMI \> 30 kg m2
- Hypertensive: PA \> 140/90 mmHg
- Normocholesterolemic (LDL\< 160 mg/dl HDL \> 35 mg/dl)
- Liver steatosis
Exclusion
- other antihypertensive treatment after wash out period of 2 weeks
- abnormal heart rest function (EF \< 55%).
- valvular heart disease
- congenital heart disease
- heart failure or prior myocardial infarction
- diabetes
- renal disease
- liver disease
- connective tissue disease
- pregnancy or lactation
- serious adverse experience
- sensitivity to the study drugs or its components
- contraindication from an approved label
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00669435
Start Date
April 1 2008
End Date
April 1 2009
Last Update
April 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pavia
Pavia, Italy